Analysis: HTA changes, more bureaucracy or faster to market?
By July this year the pharmaceutical industry may be facing a new layer of bureaucracy in making market approval reimbursement submissions but there is also hope those submissions will move faster

R&D trend means a challenging trials environment
This week the trend for major pharma companies to re-examine their commitment to R&D came into sharp focus again as AstraZeneca announced where it would implement R&D cuts revealed in general terms some weeks before